Imatinib

Nov 28, 2017

Chronic Myelogenous Leukemia Treatment Market Value to Reach US$ 8,550.8 Million by the end of 2026: Transparency Market Research

Nov 10, 2017

Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across Spectrum of KIT and PDGFRa Genotypes

Nov 01, 2017

Blueprint Medicines Announces Publication of BLU-285 Translational Data

Sep 29, 2017

Mylan Launches Generic Gleevec® Tablets

Aug 02, 2017

Blueprint Medicines Reports Second Quarter 2017 Financial Results

Jun 05, 2017

Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFRa D842V Mutation